Streetbeat News

Regulatory

ABT

CVKD

Cadrenal Therapeutics presented new trial data at the ISHLT Conference, highlighting the importance of anticoagulation quality in LVAD patients. The ARIES-HM3 Clinical Study, sponsored by Abbott, showed that tecarfarin, which recently received Orphan Drug Designation from the FDA, has the potential to improve patient outcomes.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 1:16 pm

NTGR

An ITC judge has ruled that TP-Link violated U.S. trade laws by infringing on NETGEAR's patents through the import and sale of multi-band Wi-Fi devices, routers, and mesh networking devices in the U.S.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 1:15 pm

AAPL

AMD

INTC

NVDA

TSM

Taiwan Semiconductor Manufacturing Co (TSMC) CEO C.C. Wei will become chairman, succeeding Mark Liu. Under Wei's leadership, TSMC's market value nearly tripled. The company has heavily invested in R&D and capital expenditure to stay ahead of competitors like Intel and Samsung. TSMC's stock is trading higher after a sector selloff due to the U.S. AI chip embargo on the Middle East. TSMC faces political uncertainties, and its expansion includes new sites in Japan, Germany, and the U.S. Nvidia and AMD are also mentioned in the context of competition and partnerships.

Portfolio Pulse from Anusuya Lahiri

June 03, 2024 | 1:13 pm

TSLA

Tesla Inc. (NASDAQ:TSLA) faces potential voting issues for its global shareholders ahead of a crucial vote on CEO Elon Musk's $56 billion pay package and the proposal to reincorporate the company in Texas. Cross-border voting challenges may prevent many international shareholders from participating, potentially impacting the outcome.

Portfolio Pulse from Benzinga Neuro

June 03, 2024 | 1:00 pm

GWAV

Trading halt status for GWAV was updated at 8:55:00 AM ET. The halt is due to pending news and resumption times.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:55 pm

DUO

Fangdd Network Group Ltd. (NASDAQ:DUO) and The Bank of New York Mellon plan to terminate their Deposit Agreement, leading to the termination of FangDD's ADR facility on September 4, 2024. Following this, FangDD will list its Class A ordinary shares on Nasdaq under the same symbol 'DUO'.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:45 pm

ENLV

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has received regulatory authorization from the Israeli Ministry of Health to initiate a Phase I/II trial for Allocetra™ in treating thumb osteoarthritis. This is the first study of Allocetra™ in thumb osteoarthritis, a condition with no FDA-approved therapy, and follows ongoing trials in knee osteoarthritis.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:43 pm

TIRX

TIAN RUIXIANG Holdings has regained compliance with Nasdaq's listing requirements, ensuring its continued presence on the exchange.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:38 pm

NXL

Nexalin Technology has received feedback from the FDA and reached a consensus on the design for its planned clinical studies of the Gen-3 HALO Clarity Headset Device, which targets anxiety and insomnia.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:34 pm

CEI

Camber Energy has received a Notice of Allowance for its patent application on wildfire mitigation technology, with the patent expected to be issued soon by the USPTO.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 12:33 pm